NCT04836377View on ClinicalTrials.gov

A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02

TerminatedOBSERVATIONAL
Enrollment

4

Participants

Timeline

Start Date

July 6, 2021

Primary Completion Date

August 21, 2023

Study Completion Date

August 21, 2023

Conditions
Type 1 Gaucher Disease
Interventions
OTHER

Safety and efficacy assessments

Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention

Trial Locations (3)

52242

University of Iowa, Iowa City

07601

Hackensack University Medical Center, Hackensack

T2M 0L6

M.A.G.I.C. Clinic Ltd, Calgary

Sponsors

Lead Sponsor

AVROBIO
All Listed Sponsors
lead

AVROBIO

INDUSTRY

NCT04836377 - A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02 | Biotech Hunter | Biotech Hunter